Cercetător Senior Constantin Carolina

Cercetător Senior Constantin Carolina

Institutul Naţional de Cercetare-Dezvoltare în Domeniul Patologiei şi Ştiinţelor Biomedicale “Victor Babeş” Bucureşti
Serviciul de Anatomie Patologică, Spitalul Clinic Colentina, Bucureşti

Nanomedicina în vaccinarea ANTI-SARS-COV-2
Autori: Carolina Constantin1,2, Mihaela Surcel1, Adriana Narcisa Munteanu1,3, Sabina Andrada Zurac 2,4, Monica Neagu 1, 2, 3
1Secția Imunologie, Institutul Naţional de Cercetare-Dezvoltare în Domeniul Patologiei şi Ştiinţelor Biomedicale „Victor Babeş” Bucureşti
2Serviciul de Anatomie Patologică, Spitalul Clinic Colentina, Bucureşti
3Școala Doctorală, Facultatea de Biologie, Universitatea Bucureşti
4Departamentul de Patologie, Facultatea de Medicină Dentară, Universitatea de Medicină şi Farmacie „Carol Davila”, Bucureşti

Cuvinte cheie: COVID-19; SARS-CoV-2; imunitate; nanoparticule; carrier; vaccin.

Pandemia de COVID-19 a demonstrat ca vaccinarea reprezinta cea mai puternică metodă de prevenire a infectiei, iar datele stiintifice aferente în actuala pandemie continua sa creasca într-un ritm accelerat. O nouă eră a nanomedicinei începe în domeniul dezvoltării vaccinurilor, eră care va genera noi instrumente de diagnosticare a infectiei virale și/sau de actiune antivirala. Mesagerii cheie ADN sau ARN, vehiculul de livrare a unui mesager de acest tip precum si interacțiunile acestor mesageri cu sistemul imun, converg spre suprimarea infecției cu SARS-CoV-2.
Deoarece majoritatea vaccinurilor anti-virale urmăresc în primul rând să genereze un răspuns imun mediat de anticorpi, viitorul apropiat în vaccinarea COVID-19 va necesita informații importante privind imunitatea mediata de limfocitele T și B la subiecții vaccinați. Aceste studii pot ghida dezvoltarea strategiilor de protecție eficientă împotriva SARS-CoV-2 si nu numai. Deoarece SARS-CoV-2 și diferitele sale variante vor circula probabil pentru mulți ani de acum înainte, apare necesitatea dezvoltarii de vaccinuri tot mai eficiente și sigure împotriva COVID-19, pentru mutațiile virale anticipate. Astfel, ar trebui urmărite noi formulări care extind căile de administrare și momentul vaccinării. Noile formulări pot reduce efectele secundare, iar nanomaterialele din surse naturale vor intra în fluxul de dezvoltare a vaccinurilor. In plus, viteza cu care au fost dezvoltate vaccinurile pe bază de ARNm poate conduce la o nouă eră în alte domenii, cum ar fi oncologia.
Studiu finanțat prin proiectele: PN-III-P1-1.2-PCCDI-2017-0341/2018, PN 19.29.01.01/2019.

Nanomedicine in anti sars-cov-2 vaccination
Authors: Carolina Constantin1,2, Mihaela Surcel1, Adriana Narcisa Munteanu1,3, Sabina Andrada Zurac 2, 6, Monica Neagu 1, 2, 3
1Immunology Department, „Victor Babes” National Institute of Pathology, Bucharest
2Pathology Department, „Colentina” University Hospital, Bucharest
3Doctoral School, Faculty of Biology, University of Bucharest, Bucharest
4Pathology Department, Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest

Keywords: COVID-19; SARS-CoV-2; immunity; nanoparticles; vaccine carrier; vaccines.

As the current COVID-19 pandemic illustrates, vaccination is the most powerful method of disease prevention and public confidence in vaccines depends on their safety and efficacy. The information gathered in the current pandemic is growing at an accelerated pace. Both the key vital protein DNA/RNA messengers and the delivery carriers are the elements of a puzzle including their interactions with the immune system to suppress SARS-CoV-2 infection. A new nano-era is beginning in the vaccine development field and an array of side applications for diagnostic and antiviral tools will likely emerge.
As most viral vaccines primarily aim to generate an antibody-mediated immune response, the near future in COVID-19 management would require important information regarding T and B cell immunity in both COVID-19 patients and in vaccinated subjects. These studies can guide the development of strategies for effective protection from SARS-CoV-2. Moreover, SARS-CoV-2 and its various variants will likely circulate for many years to come, efficient and safe COVID-19 vaccines should be developed and /or revisited for anticipated viral mutations. New formulations may decrease side effects, and nano-sized materials from natural sources will enter the pipeline. The speed with which the mRNA-based vaccines were developed may lead to a new era in other domains, such as oncology.
Study financed by the following projects: PN-III-P1-1.2-PCCDI-2017-0341/2018, PN 19.29.01.01/2019.

Scurt CV

Senior researcher I, PhD, biochemist, “Victor Babeș” National Institute of Pathology, Immunology Laboratory & Colentina Clinical Hospital, Research Core of Pathology Department, Bucharest.
Research topics: immune parameters analysis and biomarker discovery in melanoma and non-melanoma skin cancer; co-inventor for 4 patents related to photodynamic therapy PDT in skin pathologies. Dr. Constantin conducted national research projects related to novel photosensitizers for PDT in cancer, and drug-delivery nanosystems for skin regeneration; partner responsible for MNT_ERANET project 7030-1/2010 related to novel porphyrins in theranostics. Specialization in molecular biology at Ludwig Institute for Cancer Research, Signal Transduction Unit (Bruxelles); cellular biology specialization at University of Athens, Biochemistry and Physiology Department, in the frame of NATO SfP 982838/2007 project. Technical expert in 5 EU projects for biomedical assays; teaching experience in protein microarray technology; volunteer reviewer for several ISI journals.
Currently involved as MC member for COST Action CA18127 – International Nucleome Consortium (INC); MC substitute of the management committee for COST action CA16120 – European Epitranscriptomics Network (EPITRAN); alternate member of the management committee for CA18125 – Advanced Engineering and Research of Aerogels for Environment and Life Sciences (AEROGELS).